Martín Giménez Virna Margarita, Rukavina Mikusic Natalia Lucía, Lee Hyun Jin, García Menéndez Sebastián, Choi Marcelo Roberto, Manucha Walter
Instituto de Investigaciones en Ciencias Químicas, Facultad de Ciencias Químicas y Tecnológicas, Universidad Católica de Cuyo, Sede San Juan, Argentina.
Universidad de Buenos Aires. CONICET. Instituto Alberto C. Taquini de Investigaciones en Medicina Traslacional (IATIMET), Buenos Aires, Argentina; Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Ciencias Biológicas. Cátedra de Anatomía e Histología, Buenos Aires, Argentina.
Biochem Pharmacol. 2022 Oct;204:115213. doi: 10.1016/j.bcp.2022.115213. Epub 2022 Aug 17.
The gut microbiota dysbiosis represents a triggering factor for cardiovascular diseases, including hypertension. In addition to the harmful impact caused by hypertension on different target organs, gut dysbiosis is capable of causing direct damage to critical organs such as the brain, heart, blood vessels, and kidneys. In this sense, it should be noted that pharmacological and nutritional interventions may influence gut microbiota composition, either inducing or preventing the development of hypertension. Some of the most important nutritional interventions at this level are represented by pro-, pre-, post- and/or syn-biotics, as well as polysaccharides, polyunsaturated fatty acids ω-3, polyphenols and fiber contained in different foods. Meanwhile, certain natural and synthetic active pharmaceutical ingredients, including antibiotics, antihypertensive and immunosuppressive drugs, vegetable extracts and vitamins, may also have a key role in the modulation of both gut microbiota and cardiovascular health. Additionally, gut microbiota may influence drugs and food-derived bioactive compounds metabolism, positively or negatively affecting their biological behavior facing established hypertension. The understanding of the complex interactions between gut microbiome and drug/food response results of great importance to developing improved pharmacological therapies for hypertension prevention and treatment. The purpose of this review is to critically outline the most relevant and recent findings on cardiovascular, renal and brain physiopathological mechanisms involved in the development of hypertension associated with changes in gut microbiota, besides the nutritional and pharmacological interventions potentially valuable for the prevention and treatment of this prevalent pathology. Finally, harmful food/drug interventions on gut microbiota are also described.
肠道微生物群失调是包括高血压在内的心血管疾病的触发因素。除了高血压对不同靶器官造成的有害影响外,肠道失调还会对大脑、心脏、血管和肾脏等关键器官造成直接损害。从这个意义上说,应该注意到药物和营养干预可能会影响肠道微生物群的组成,从而诱发或预防高血压的发展。这一水平上一些最重要的营养干预措施包括益生元、益生菌、合生元和/或后生元,以及不同食物中所含的多糖、多不饱和脂肪酸ω-3、多酚和纤维。同时,某些天然和合成的活性药物成分,包括抗生素、抗高血压和免疫抑制药物、植物提取物和维生素,在调节肠道微生物群和心血管健康方面也可能起关键作用。此外,肠道微生物群可能会影响药物和食物衍生的生物活性化合物的代谢,对它们面对已确诊高血压时的生物学行为产生正面或负面影响。了解肠道微生物群与药物/食物反应之间的复杂相互作用对于开发改进的高血压预防和治疗药物疗法非常重要。本综述的目的是批判性地概述与肠道微生物群变化相关的高血压发展过程中涉及的心血管、肾脏和大脑生理病理机制的最新相关研究结果,以及对预防和治疗这种常见疾病可能有价值的营养和药物干预措施。最后,还描述了有害的食物/药物对肠道微生物群的干预。